雄激素受体剪接变异体7在去势抵抗性前列腺癌中的作用及其临床意义

摘要
图/表
参考文献(31)
相关文章 (15)

全文: PDF (578 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要去势抵抗性前列腺癌（CRPC）是经过初次持续内分泌治疗后仍然进展的前列腺癌。CRPC的发生和发展机制极其复杂，目前尚未完全研究清楚，但雄激素受体（AR）信号的持续激活仍是重要因素。雄激素受体剪接变异体7（AR-V7）是AR重要的变异体之一，其与CRPC发生、发展存在密切联系，在促进AR的再活化、肿瘤的生长转移以及耐药性的产生中起着重要作用，与内分泌治疗的敏感性和总体存活率降低相关，是一种潜在评价指标，深入研究AR-V7与CRPC的关系，不仅可以指导现阶段CRPC的用药，还可以为CRPC的治疗提供新的途径和方向。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张烨王磊张璐钟云萍刘修恒

关键词 ：前列腺癌, 去势抵抗性前列腺癌, 雄激素受体, 雄激素受体剪接变异体7, 临床意义

Abstract：Castration-resistant prostate cancer (CRPC) is a prostate cancer that progresses after initial sustained endocrine therapy. The mechanism of CRPC occurrence and development is extremely complicated and has not been fully studied yet, but the continuous activation of androgen receptor (AR) signal is still an important factor. Androgen receptor splice variants 7 (AR-V7) is one of the most important variants of AR. Many studies have shown that it is closely related to the development of CRPC, promoting AR reactivation, tumor growth and metastasis. It plays an important role in the development of drug resistance, and is associated with the sensitivity of endocrine therapy and the overall survival rate. It is a potential evaluation index. In-depth study of the relationship between AR-V7 and CRPC can not only guide the current use of CRPC, it can also provide new ways and directions for the treatment of CRPC.

Key words： Prostate cancer Castration-resistant prostate cancer Androgen receptor Androgen receptor splice variant 7 Clinical significance

基金资助:中央高校基本科研业务费专项资金项目（2042019kf0091）。

通讯作者: 刘修恒（1962-），男，博士，教授，博士研究生导师；研究方向：泌尿外科肿瘤。

作者简介: 张烨（1994-），男，硕士；研究方向：泌尿系外科肿瘤。

引用本文:

张烨王磊张璐钟云萍刘修恒. 雄激素受体剪接变异体7在去势抵抗性前列腺癌中的作用及其临床意义[J]. 中国医药导报, 2020, 17(1): 46-49.
ZHANG Ye WANG Lei ZHANG Lu ZHONG Yunping LIU Xiuheng. Role of androgen receptor splice variants 7 in castration-resistant prostate cancer and its clinical significance. 中国医药导报, 2020, 17(1): 46-49.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I1/46

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
[2] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[3] Chandrasekar T，Yang JC，Gao AC，et al. Mechanisms of resistance in castration-resistant prostate cancer （CRPC） [J]. Transl Androl Urol，2015，4（3）：365-380.
[4] Zhang M，Sun Y，Meng J，et al. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth [J]. Cancer Lett，2019，442（3）：483-490.
[5] Takayama KI. Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling [J]. Biomolecules，2019，9（4）：13101-13113.
[6] Sciarra A，Gentilucci A，Silvestri I，et al. Androgen receptor variant 7 （AR-V7） in sequencing therapeutic agents for castratrion resistant prostate cancer：a critical review [J]. Medicine （Baltimore），2019，98（19）：e1560801-e1560808.
[7] Friedlander TW，Ryan CJ. Targeting the androgen receptor [J]. Urol Clin North Am，2012，39（4）：453-464.
[8] Dehm SM，Schmidt LJ，Heemers HV，et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance [J]. Cancer Res，2008，68（13）：5469-5477.
[9] Martinez-Breijo S，Chantada-Abal V，Aller-Rodriguez M，et al. Castration resistance mechanisms in prostate cancer [J]. Arch Esp Urol，2018，71（8）：628-638.
[10] Dalal K，Ban F，Li H，et al. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer [J]. Cancer Lett，2018，437（22）：35-43.
[11] Minges JT，Su S，Grossman G，et al. Melanoma antigen-A11 （MAGE-A11） enhances transcriptional activity by linking androgen receptor dimers [J]. J Biol Chem，2013，288（3）：1939-1952.
[12] Wang Q，Li W，Zhang Y，et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer [J]. Cell，2009，138（2）：245-256.
[13] Boudadi K，Suzman DL，Anagnostou V，et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer [J]. Oncotarget，2018， 9（47）：28561-28571.
[14] Gelmann EP. Molecular biology of the androgen receptor [J]. J Clin Oncol，2002，20（13）：3001-3015.
[15] Qu Y，Dai B，Ye D，et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer [J]. Sci Rep，2015，5：765401-765406.
[16] Cato L，de Tribolet-Hardy J，Lee I，et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer [J]. Cancer Cell，2019，35（3）：401-413.
[17] Sun F，Chen HG，Li W，et al. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors [J]. J Biol Chem，2014，289（3）：1529-1539.
[18] Fizazi K，Tran N，Fein L，et al. Abiraterone plus prednisone in metastatic，castration-sensitive prostate cancer [J]. N Engl J Med，2017，377（4）：352-360.
[19] Mostaghel EA，Marck BT，Plymate SR，et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer：induction of steroidogenesis and androgen receptor splice variants [J]. Clin Cancer Res，2011，17（18）：5913-5925.
[20] Wu G，Sun Y，Xiang Z，et al. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression [J]. Cell Death Dis，2019，10（2）：3701-3714.
[21] Antonarakis ES，Lu C，Wang H，et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer [J]. N Engl J Med，2014，371（11）：1028-1038.
[22] Shan X，Danet-Desnoyers G，Aird F，et al. Replication study：androgen receptor splice variants determine taxane sensitivity in prostate cancer [J]. Peer J，2018，6（20）：e466101-e466111.
[23] Thadani-Mulero M，Nanus DM，Giannakakou P. Androgen receptor on the move：boarding the microtubule expressway to the nucleus [J]. Cancer Res，2012，72（18）：4611-4615.
[24] Antonarakis ES，Lu C，Luber B，et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer [J]. Jama Oncol，2015，1（5）：582-591.
[25] Bastos DA，Antonarakis ES. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer [J]. Expert Rev Mol Diagn，2018，18（2）：155-163.
[26] Bryce AH，Antonarakis ES. Androgen receptor splice variant 7 in castration-resistant prostate cancer：clinical considerations [J]. Int J Urol，2016，23（8）：646-653.
[27] Wadosky KM，Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer [J]. Oncotarget，2016，7（39）：64447-64470.
[28] Elshan N，Rettig MB，Jung ME. Molecules targeting the androgen receptor （AR） signaling axis beyond the AR-Ligand binding domain [J]. Med Res Rev，2019，39（3）：910-960.
[29] Fan L，Zhang F，Xu S，et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 （AR-V7） in prostate cancer cells [J]. Proc Natl Acad Sci USA，2018，115（20）：E4584-E4593.
[30] Lin SJ，Chou FJ，Li L，et al. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 （ARv7） [J]. Cancer Lett，2017， 398（13）：62-69.
[31] Hu WY，Xu L，Chen B，et al. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75 [J]. Prostate，2019，79（10）：1166-1179.